MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population

• DOI: 10.1371/journal.pone.0220670
• Publication Date: 2019-08-01T17:42:59Z
• Authors: Jrhau Lung; Ming-Szu Hung; Yu-Ching Lin; Kam-Fai Lee; Yuan Yuan Jiang; Shao-Lan Huang; Yu-Hung Fang; Ming-Shian Lu; Chin-Kuo Lin; Tsung-Ming Yang; Paul Yann Lin; Meng-Jer Hsieh; Ying Huang Tsai
• Keywords: Adult; Male; Lung Neoplasms; Science; Taiwan; Adenocarcinoma; Real-Time Polymerase Chain Reaction; 03 medical and health sciences; 0302 clinical medicine; Carcinosarcoma; Humans; In Situ Hybridization, Fluorescence; Aged; Aged, 80 and over; Q; R; Gene Amplification; Exons; Middle Aged; Proto-Oncogene Proteins c-met; 3. Good health; Gene Expression Regulation, Neoplastic; Mutation; Medicine; Female; Research Article

Somatic mutations of MET gene are emerging as important driver for lung cancers. To identify the common clinicopathological features exon 14 skipping and amplification clarify whether two alterations cause protein overexpression were investigated using 196 cancer samples Taiwan through real time-qPCR/sequencing, fluorescence in situ hybridization, immunohistochemistry. The both present low frequency, ~1%, studied population Taiwan. identified from early-stage patients, who relatively advanced age, did not carry other mutations. One was an adenocarcinoma a rare carcinosarcoma. Three amplifications cases identified. Neither would lead to overexpression; hence, direct detection nucleic acid level be preferred straightforward solution identification presence minor histological types cancers urge extend screening scope this mutation treatment response evaluation clinical trials. These next steps success target therapy practice.